evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

699 questions · 745 findings · 185 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 180 · 24.2%GRADE not reported 76 · 10.2%Very low 194 · 26%Low 154 · 20.7%Moderate 110 · 14.8%High 31 · 4.2%

Benzodiazepines vs placebo

Acceptability · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether benzodiazepines changes acceptability of the treatment (measured by participants leaving the… compared with placebo (very low certainty).

1 finding from 1 review

Intervention not reported

Acceptability of treatment ‐ leaving the study early · people with antipsychotic‐induced tardive dyskinesia

The review found no eligible studies for this question.

1 finding from 1 review

Buspirone vs placebo

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANXIOLYTIC ‐ BUSPIRONE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

FATTY ACID ‐ ETHYL‐EPA vs placebo

Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Ginkgo biloba vs placebo

Leaving the study early · male 45.2 (mean) years old patients with schizophrenia and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether HERB ‐ GINKGO BILOBA changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

POLYPEPTIDE ‐ CERULETIDE vs placebo

Leaving the study early · female and male 55‐59 year old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive dyskinesia

It is very uncertain whether POLYPEPTIDE ‐ CERULETIDE changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS vs placebo

Leaving the study early · female and male 59‐80 (mean) years old patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ALKALOID ‐ DIHYDROGENATED ERGOT ALKALOIDS changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Levetiracetam vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Vitamin E vs placebo

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether VITAMIN E changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).

1 finding from 1 review

Switch to another antipsychotic vs antipsychotic cessation

Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).

1 finding from 1 review

Specific antipsychotic vs other drugs

Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia

It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).

1 finding from 1 review